skip to Main Content

Prophylaxis and immunotherapy of S. aureus/MRSA disease

Staphylococcus aureus (SA) is a Gram-positive bacterium that colonizes approximately one-third of the human population1.  It causes a wide range of diseases from skin and soft tissue infections (SSTI) to life-threatening systemic diseases such as bacteremia and pneumonia with high mortality rates2,3.  Currently, methicillin-resistant S. aureus (MRSA) is killing as many people…

Read More
Back To Top
Search
Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.